Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus abiraterone as first-line therapy in metastatic castration-resistant prostate cancer
NL-OMON59043Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Olaparib + abiraterone with Placebo + abiraterone (2 arms). Primary endpoint: Radiological progression-free survival. Started Apr 2019; status: completed.
02
Drugs
olaparibabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON59043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59043.